JPMorgan analyst Eric Joseph reiterated an Overweight rating and $48.00 price target on Beam ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'November 5, 2024 11:47 AM Form 10-Q Beam Therapeutics Inc. For: Sep 30November 5, 2024 9:06 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 9:00 AM Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ANovember 5, 2024 9:00 AM BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'November 5, 2024 8:58 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 8:31 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 7:05 AM Beam, Inc. (BEAM) Tops Q3 EPS by 1cNovember 5, 2024 6:39 AM Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNovember 5, 2024 6:30 AM